| |
Controls
|
HIV+
|
|---|
| |
N = 10
|
N = 43
|
|---|
| |
Median or n
|
IQR or %
|
Median or n
|
IQR or %
|
|---|
|
Demography and lifestyle
| | | | |
|
Age (years)
|
48.1
|
41.9–62.3
|
49.8
|
43.3–55.2
|
|
Smoking
|
0
|
0 %
|
14*
|
32.6 %
|
|
Body composition
| | | | |
|
Lipodystrophy
|
—
|
—
|
14
|
32.6 %
|
|
BMI (kg/m2)
|
25.4
|
24.7–28.6
|
25.1
|
23.0–27.7
|
|
FMI (kg/m2)
|
5.2
|
4.6–7.5
|
4.6
|
3.4–6.4
|
|
VAT (cm2)
|
111.6
|
93.5–157.5
|
150.8
|
115.0–212.2
|
|
lLMI (kg/m2)
|
6.4
|
6.2–6.8
|
6.1
|
5.7–6.6
|
|
Metabolic parameters
| | | | |
|
HOMA-IR
|
0.5
|
0.5–1.3
|
1.2*
|
0.6–2.4
|
|
Metabolic syndrome
|
1
|
10 %
|
20
|
46.5 %
|
|
Biomarkers of inflammation
| | | | |
|
IL-6 (pg/mL)
|
1.1
|
0.7–2.4
|
1.6
|
1.1–2.6
|
|
suPAR (ng/mL)
|
1.8
|
1.5–2.1
|
2.2*
|
1.8–2.8
|
|
HIV- and immune-related parameters
| | | | |
|
HIV duration (years)
|
—
|
—
|
14
|
6.6–21.0
|
|
ART duration (years)
|
—
|
—
|
10.2
|
4.4–14.8
|
|
Current PI treatment
|
—
|
—
|
13
|
30.2 %
|
|
Current NRTI treatment
|
—
|
—
|
43
|
100 %
|
|
Current NNRTI treatment
|
—
|
—
|
28
|
65.1 %
|
|
Other current ART
|
—
|
—
|
4
|
9.30 %
|
|
HIV RNA ≤20 copies/mL
|
—
|
—
|
39
|
90.7 %
|
|
CD4+ T cell count (cells/μL)
|
729
|
674–880
|
580
|
403–820
|
|
CD8+ T cell count (cells/μL)
|
373
|
281–440
|
828***
|
618–1120
|
|
CD4:CD8 ratio
|
2.0
|
1.8–3.0
|
0.7***
|
0.5–1.0
|
- Continuous measures are listed as: median and interquartile range. Categorical variables are listed as: number of participants and percentage
- Abbreviations: BMI body mass index, ART antiretroviral therapy, FMI fat mass index, HOMA-IR homeostatic model assessment of insulin resistance, IL-6 interleukin-6, IQR interquartile range, lLMI leg lean mass index, NRTI nucleoside reverse-transcriptase inhibitors, NNRTI non-nucleoside reverse-transcriptase inhibitor, PI protease inhibitor, suPAR soluble urokinase plasminogen activator receptor, VAT visceral adipose tissue
- The bold values are statistically significant at *
P < 0.05, **
P < 0.01, ***
P < 0.001
